Merrimack Pharmaceuticals (MACK) Short Interest Ratio & Short Volume → Biden replacement revealed? (From Paradigm Press) (Ad) Free MACK Stock Alerts $15.00 -0.03 (-0.20%) (As of 05/3/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Merrimack Pharmaceuticals Short Interest DataCurrent Short Volume815,900 sharesPrevious Short Volume722,800 sharesChange Vs. Previous Month+12.88%Dollar Volume Sold Short$11.98 millionShort Interest Ratio / Days to Cover6.4Last Record DateApril 15, 2024Outstanding Shares14,530,000 sharesPercentage of Shares Shorted5.62%Today's Trading Volume187,592 sharesAverage Trading Volume113,841 sharesToday's Volume Vs. Average165% Short Selling Merrimack Pharmaceuticals ? Sign up to receive the latest short interest report for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatMACK Short Interest Over TimeMACK Days to Cover Over TimeMACK Percentage of Float Shorted Over Time Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report Merrimack Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2024815,900 shares $11.98 million +12.9%N/A6.4 $14.68 3/31/2024722,800 shares $10.68 million -1.0%N/A6.2 $14.77 3/15/2024729,900 shares $10.76 million -5.7%N/A7 $14.74 2/29/2024774,100 shares $11.38 million -5.9%N/A8.4 $14.70 2/15/2024822,900 shares $12.10 million +7.9%N/A9.7 $14.70 1/31/2024763,000 shares $10.22 million +1.5%N/A16.8 $13.40 Get the Latest News and Ratings for MACK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/2024752,100 shares $9.91 million -3.8%N/A18.8 $13.17 12/31/2023781,400 shares $10.48 million -10.4%N/A20.1 $13.41 12/15/2023871,600 shares $11.54 million -3.6%N/A23.4 $13.24 11/30/2023904,300 shares $11.41 million -1.8%N/A26.4 $12.62 11/15/2023921,100 shares $11.76 million -0.5%N/A27 $12.77 10/31/2023926,100 shares $11.33 million -2.6%N/A27.2 $12.23 10/15/2023951,100 shares $11.67 million -3.5%N/A21.3 $12.27 9/30/2023985,100 shares $12.15 million -5.3%N/A19.1 $12.33 9/15/20231,040,000 shares $12.73 million -2.8%N/A10.5 $12.24 8/31/20231,070,000 shares $13.06 million -2.7%N/A10.2 $12.21 8/15/20231,100,000 shares $13.38 million +1.9%N/A10.2 $12.16 7/31/20231,080,000 shares $12.97 million +3.9%N/A9.4 $12.01 7/15/20231,040,000 shares $12.15 million +5.4%N/A9.5 $11.68 6/30/2023986,900 shares $12.14 million +38.3%N/A9.2 $12.30 6/15/2023713,500 shares $8.84 million +4.4%N/A7.4 $12.39 5/31/2023683,700 shares $8.56 million -5.1%N/A9.2 $12.52 5/15/2023720,200 shares $9.20 million -8.8%N/A9.5 $12.77 4/30/2023789,600 shares $9.80 million -12.7%6.0%9.8 $12.41 4/15/2023904,700 shares $11.62 million +6.7%6.9%9.9 $12.84 3/31/2023847,700 shares $10.42 million -5.2%6.5%7 $12.29 3/15/2023894,500 shares $10.33 million -4.7%6.9%6.2 $11.55 2/28/2023938,100 shares $10.77 million -2.7%7.7%6 $11.48 2/15/2023964,000 shares $11.24 million +3.6%7.4%5.9 $11.66 1/31/2023930,300 shares $10.78 million +11.1%7.1%1.2 $11.59 1/15/2023837,100 shares $10.13 million +4.1%6.4%1.1 $12.10 12/30/2022804,300 shares $9.22 million +60.9%7.2%1.1 $11.46 12/15/2022499,800 shares $5.77 million -23.1%4.5%0.7 $11.55 11/30/2022649,800 shares $7.74 million -23.1%5.8%1 $11.91 11/15/2022844,700 shares $10.39 million +226.0%7.5%1.3 $12.30 10/31/2022259,100 shares $976,807.00 +1.0%2.3%0.5 $3.77 10/15/2022256,600 shares $857,044.00 -0.8%2.3%7 $3.34 9/30/2022258,700 shares $970,125.00 +2.0%2.3%8 $3.75 9/15/2022253,700 shares $1.11 million -2.8%2.3%8.7 $4.38 8/31/2022261,000 shares $1.08 million +0.9%2.3%8.8 $4.15Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report MACK Short Interest - Frequently Asked Questions What is Merrimack Pharmaceuticals' current short interest? Short interest is the volume of Merrimack Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 815,900 shares of MACK short. Learn More on Merrimack Pharmaceuticals' current short interest. What is a good short interest ratio for Merrimack Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MACK shares currently have a short interest ratio of 6.0. Learn More on Merrimack Pharmaceuticals's short interest ratio. Is Merrimack Pharmaceuticals' short interest increasing or decreasing? Merrimack Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 815,900 shares, an increase of 12.9% from the previous total of 722,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Merrimack Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Merrimack Pharmaceuticals: Rigel Pharmaceuticals, Inc. (2.95%), Verastem, Inc. (3.94%), Vanda Pharmaceuticals Inc. (3.80%), Regulus Therapeutics Inc. (10.92%), XOMA Co. (2.42%), Emergent BioSolutions Inc. (11.76%), Lexicon Pharmaceuticals, Inc. (8.17%), OPKO Health, Inc. (23.81%), Ovid Therapeutics Inc. (4.78%), Galectin Therapeutics Inc. (6.47%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Merrimack Pharmaceuticals stock? Short selling MACK is an investing strategy that aims to generate trading profit from Merrimack Pharmaceuticals as its price is falling. MACK shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Merrimack Pharmaceuticals? A short squeeze for Merrimack Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MACK, which in turn drives the price of the stock up even further. How often is Merrimack Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MACK, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Rigel Pharmaceuticals Short Interest Verastem Short Interest Vanda Pharmaceuticals Short Interest Regulus Therapeutics Short Interest XOMA Short Interest Emergent BioSolutions Short Interest Lexicon Pharmaceuticals Short Interest OPKO Health Short Interest Ovid Therapeutics Short Interest Galectin Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MACK) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsBiden Nomination CANCELED?The Freeport SocietyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace